Fig. 3: Prophylactic effects of (R)-ketamine on the expression of NFATc4 in the PFC after LPS injection.
A Nfatc4 mRNA in the PFC (one way ANOVA: F2,28 = 17.84, P < 0.0001). B There was a positive correlation (R = 0.744, P < 0.0001) between spleen weight and Nfatc4 mRNA in the PFC. C There was a positive correlation (R = 0.544, P = 0.002) between plasma interleukin (IL)-6 and Nfatc4 mRNA in the PFC. D There was a positive correlation (R = 0.637, P < 0.0001) between plasma tumor necrosis factor (TNF)-α and Nfatc4 mRNA in the PFC. E Cd4 mRNA in the PFC (one way ANOVA: F2,28 = 16.16, P < 0.0001). F Cd79b mRNA in the PFC (one way ANOVA: F2,28 = 30.40, P < 0.0001). G H2-ab1 mRNA in the PFC (one way ANOVA: F2,28 = 12.81, P = 0.0001). H H2-aa mRNA in the PFC (one way ANOVA: F2,28 = 5.617, P = 0.009). I The protein expression of PSD-95 in the PFC (one way ANOVA: F2,27 = 5.506, P = 0.010). The data represent mean ± S.E.M. (n = 9–11). *P < 0.05, **P < 0.01, ***P < 0.001. J The protein expression of NFATc4 in the parietal cortex from controls (n = 15) and MDD patients (n = 15) (Man–Whitney U-test: U = 60.00, P = 0.030). The data represent mean ± S.E.M. (n = 15). *P < 0.05.